ReviewEndocrine2015
Classification of lung neuroendocrine tumors: lights and shadows.
Review in Endocrine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04790708 (Peptide Receptor Radionuclide Therapy), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Article
- Improvement of pathological staging system for neuroendocrine tumors of the lung.Annals of translational medicine · 2021Article
- Article
- Article
- Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature.Lung Cancer (Auckland, N.Z.) · 2020Review
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia in a young man with hypoxia: a case report and review of the literature.Acta bio-medica : Atenei Parmensis · 2019Review
- Cancer stem-neuroendocrine cells in an atypical carcinoid case report.Translational lung cancer research · 2019Article
- CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications.Cancer cytopathology · 2019Article
- Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids.Cancer research · 2019Article
- [Systemic Therapy for Low-grade Pulmonary Neuroendocrine Tumor].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.Journal of thoracic disease · 2018Article
- Advanced typical and atypical carcinoid tumours of the lung: management recommendations.Current oncology (Toronto, Ont.) · 2018Review
- Management of pulmonary neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2017Review
- Lung neuroendocrine tumors: pathological characteristics.Journal of thoracic disease · 2017Review
- Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.Therapeutic advances in medical oncology · 2017Review
- Low Grade Neuroendocrine Tumors of the Lung.Frontiers in oncology · 2017Review
- [Grading of neuroendocrine tumors].Der Pathologe · 2016Review
- [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].Der Pathologe · 2015Review
- Pulmonary neuroendocrine carcinoid tumors: Is there a predictive role to the Ki 67 index?Annals of thoracic medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors of the lung are classified into low-grade typical and intermediate-grade atypical carcinoids, and high-grade poorly differentiated neuroendocrine carcinomas of the large and small cell types. This scheme is strongly predictive of patients' prognosis but relies on few and scarcely reproducible pathological parameters (namely mitotic count and assessment of the presence of necrosis), which have been demonstrated to affect the inter-observer agreement of the classification. Moreover, tumor and nodal staging schemes are not specific for lung carcinoids, at variance with neuroendocrine tumors of the gastro-entero-pancreatic system, despite these tumors have specific features that strongly differ from conventional lung cancer. Finally, there is no grading for lung neuroendocrine neoplasms and prognostication, as well as the definition of treatment modalities and clinical strategies, which are based on tumor histotypes, only. However, literature data indicate that the evaluation of Ki-67 proliferation index may be a reliable and useful tool to determine the biological and clinical behavior of neuroendocrine tumors, with special reference to carcinoids, both in pre-operative and surgical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.